Back to top

vaccines: Archive

Sundeep Ganoria

Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS

President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.

SNYPositive Net Change BIIBPositive Net Change NVAXPositive Net Change CSTLPositive Net Change

Zacks Equity Research

Novavax to Report Q3 Earnings: Here's What to Expect

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.

SNYPositive Net Change NVAXPositive Net Change WVEPositive Net Change LEGNNegative Net Change

Urmimala Biswas

5 PEG-Based GARP Stocks to Buy Amid Election Week Volatility

Here are five stocks with a discounted PEG ratio, BABA, PFE, VIRT, LDOS and EAT, suitable for GARP investors.

PFEPositive Net Change EATNegative Net Change LDOSPositive Net Change BABANegative Net Change VIRTPositive Net Change

Sundeep Ganoria

Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.

AZNPositive Net Change MRKPositive Net Change CSTLPositive Net Change ELEVPositive Net Change

Zacks Equity Research

GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change

Zacks Equity Research

Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions

Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.

ALNYPositive Net Change PFEPositive Net Change ANIPPositive Net Change CSTLPositive Net Change